Stock HLS HLS THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Market Closed - Toronto S.E.
Other stock markets
 01:59:08 2024-06-04 pm EDT 		5-day change 1st Jan Change
3.77 CAD +1.34% Intraday chart for HLS Therapeutics Inc. +0.27% -4.56%
May. 28 HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study MT
May. 28 HLS Therapeutics Inc. Announces New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment CI

Evolution of the average Target Price on HLS Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

99512b5.JmZ33QS0SUPiO1e4PHlXdSfB3ED0UWHWOs7BYQjREA8.YhEimHKBOgmWTw3ySBpuLEOtuQucaTLuCqqWNj-zY11QPBKzfP0MHLhONA~b537566044503f70c33a03d4c0698ba9

Analyst Recommendations on HLS Therapeutics Inc.

HLS Therapeutics Downgraded to Hold at Stifel GMP on Revenue Concerns; Price Target Cut to C$5.00 MT
HLS Therapeutics Buy Rating Maintained at Stifel GMP as Growth Expectations Eased; Price Target Cut to C$12.25 MT
HLS Therapeutics Brief: Announcing Updates to its Credit Agreement; Term Extended, Borrowing capacity increases, Financial flexibility improves, and Interest rates remain relatively unchanged MT
HLS Therapeutics Buy Rating Reiterated at Stifel GMP as Vascepa Prescriptions Rise; Price Target Kept at C$26.00 MT
HLS Therapeutics Reiterated at Buy at Stifel GMP on Rising Sales; Price Target Kept at C$32.00 MT
HLS Therapeutics Keeps Buy Rating at Stifel GMP Following Q2 Results; Price Target Cut to C$32.00 MT
HLS Therapeutics Buy Rating Maintained by Stifel GMP as Vascepa Sales Expand MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.755 USD
Average target price
3.885 USD
Spread / Average Target
+40.99%
High Price Target
6.953 USD
Spread / Highest target
+152.35%
Low Price Target
2.74 USD
Spread / Lowest Target
-0.56%

Consensus detail

Consensus revision (last 18 months)

Analysts covering HLS Therapeutics Inc.

Stifel GMP

Ratings for HLS Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. HLS Stock
  4. Consensus HLS Therapeutics Inc.